174 related articles for article (PubMed ID: 23418666)
1. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
Tolkach Y; Joniau S; Van Poppel H
BJU Int; 2013 Jun; 111(7):1021-30. PubMed ID: 23418666
[TBL] [Abstract][Full Text] [Related]
2. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
Rick FG; Schally AV
Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
[TBL] [Abstract][Full Text] [Related]
3. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
4. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
5. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
Engel JB; Schally AV
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
[TBL] [Abstract][Full Text] [Related]
6. The role of LHRH antagonists in the treatment of prostate cancer.
Crawford ED; Hou AH
Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
[TBL] [Abstract][Full Text] [Related]
7. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.
Kluth LA; Shariat SF; Kratzik C; Tagawa S; Sonpavde G; Rieken M; Scherr DS; Pummer K
World J Urol; 2014 Jun; 32(3):669-76. PubMed ID: 23999854
[TBL] [Abstract][Full Text] [Related]
8. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
9. Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists.
Labrie F; Bélanger A; Kelly PA; Séguin C; Cusan L; Lefebvre FA; Reeves JJ; Lemay A; Faure N; Gourdeau Y; Raynaud JP
Prog Clin Biol Res; 1981; 74():273-91. PubMed ID: 6275404
[TBL] [Abstract][Full Text] [Related]
10. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
11. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
[TBL] [Abstract][Full Text] [Related]
12. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.
Liu SV; Liu S; Pinski J
Expert Opin Investig Drugs; 2011 Jun; 20(6):769-78. PubMed ID: 21449823
[TBL] [Abstract][Full Text] [Related]
14. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
16. The different mechanisms for suppression of pituitary and testicular function.
Sandow J; Engelbart K; von Rechenberg W
Med Biol; 1986; 63(5-6):192-200. PubMed ID: 3010006
[TBL] [Abstract][Full Text] [Related]
17. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
18. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Kirby RS; Fitzpatrick JM; Clarke N
BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
[TBL] [Abstract][Full Text] [Related]
19. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
20. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
Garnick MB; Campion M
Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
